1. Home
  2. |Insights
  3. |Saudi Arabia Changes Weekend to Friday/Saturday from 29 June 2013

Saudi Arabia Changes Weekend to Friday/Saturday from 29 June 2013

Client Alert | 1 min read | 06.24.13

On June 23, 2013, H.M. King Abdullah bin Abdulaziz Al Saud issued Royal Order No. O/185 changing the Saudi Arabian weekend from the current Thursday - Friday to Friday -Saturday.

This change brings the Kingdom's working week in line with that of the other member states of the Cooperation Council of the Arab States of the Gulf (GCC).

The change applies as follows:

1.) Effective Saturday June 29, 2013, the new Friday / Saturday weekend will apply to all Saudi Arabian Ministries, the Saudi Arabian Monetary Agency and all financial institutions, as well as the Capital Markets Authority and Saudi Stock Exchange (Tadawul);

2.) Effective for the 2013-14 Academic Year, the new Friday / Saturday weekend will apply to all academic institutions including schools and universities.

The Saudi Press Agency said, "The decision was  taken due to the crucial importance to achieve the largest homogeneity of weekly working days between agencies, governmental departments, national institutions, and their counterparts at the regional and international levels, and also due to the obvious interests and significant gains for the Kingdom, particularly in the economic aspects. It was also taken for putting an end to the negative effects and lost economic opportunities consistently associated with variation based on some working days between those agencies, institutions and national bodies and their international and regional counterparts."

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...